146 related articles for article (PubMed ID: 30280953)
41. Toxicity of polymeric nanoparticles in vivo and in vitro.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
J Nanopart Res; 2014 Jun; 16(6):. PubMed ID: 26420981
[TBL] [Abstract][Full Text] [Related]
42. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
[TBL] [Abstract][Full Text] [Related]
43. Comparison between Polybutylcyanoacrylate Nanoparticles with Either Surface-Adsorbed or Encapsulated Brain-Derived Neurotrophic Factor on the Neural Differentiation of iPSCs.
Lin MH; Chung CY; Chen KT; Yeh JC; Lee TH; Lee MH; Lee IN; Huang WC; Yang JT
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621332
[TBL] [Abstract][Full Text] [Related]
44. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
[TBL] [Abstract][Full Text] [Related]
45. Protein-functionalized nanoparticles derived from end-functional polymers and polymer prodrugs for crossing the blood-brain barrier.
Cox A; Vinciguerra D; Re F; Magro RD; Mura S; Masserini M; Couvreur P; Nicolas J
Eur J Pharm Biopharm; 2019 Sep; 142():70-82. PubMed ID: 31176723
[TBL] [Abstract][Full Text] [Related]
46. [Research on Tat peptide-polyethylene glycol modified gelatin-siloxane nanoparticles across the blood-brain barrier].
Tian X; Wei F; Lin X; Feng W; Wang P
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):486-90, 500. PubMed ID: 22826945
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo evaluation of 10-hydroxycamptothecin-loaded poly (n-butyl cyanoacrylate) nanoparticles prepared by miniemulsion polymerization.
Jin X; Asghar S; Zhu X; Chen Z; Tian C; Yin L; Ping Q; Xiao Y
Colloids Surf B Biointerfaces; 2018 Feb; 162():25-34. PubMed ID: 29145001
[TBL] [Abstract][Full Text] [Related]
48. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
49. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity.
Kim JH; Kim JH; Kim KW; Kim MH; Yu YS
Nanotechnology; 2009 Dec; 20(50):505101. PubMed ID: 19923650
[TBL] [Abstract][Full Text] [Related]
50. Nanoparticle surface charges alter blood-brain barrier integrity and permeability.
Lockman PR; Koziara JM; Mumper RJ; Allen DD
J Drug Target; 2004; 12(9-10):635-41. PubMed ID: 15621689
[TBL] [Abstract][Full Text] [Related]
51. Functional Characterization of Carrier-Mediated Transport of Pravastatin across the Blood-Retinal Barrier in Rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Drug Metab Dispos; 2015 Dec; 43(12):1956-9. PubMed ID: 26431714
[TBL] [Abstract][Full Text] [Related]
52. Development of Blood-Brain Barrier Permeable Nanoparticles as Potential Carriers for Salvianolic Acid B to CNS.
Grossi C; Guccione C; Isacchi B; Bergonzi MC; Luccarini I; Casamenti F; Bilia AR
Planta Med; 2017 Mar; 83(5):382-391. PubMed ID: 27002395
[TBL] [Abstract][Full Text] [Related]
53. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.
Jin X; Huang A; Ping Q; Cao F; Su Z
Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067
[TBL] [Abstract][Full Text] [Related]
54. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers.
Geldenhuys W; Wehrung D; Groshev A; Hirani A; Sutariya V
Pharm Dev Technol; 2015 Jun; 20(4):497-506. PubMed ID: 24597667
[TBL] [Abstract][Full Text] [Related]
55. Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Zhang X; Liu L; Chai G; Zhang X; Li F
Drug Dev Ind Pharm; 2013 Nov; 39(11):1618-24. PubMed ID: 24087853
[TBL] [Abstract][Full Text] [Related]
56. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
57. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns.
Göppert TM; Müller RH
J Drug Target; 2005 Apr; 13(3):179-87. PubMed ID: 16036306
[TBL] [Abstract][Full Text] [Related]
58. Occipital blood-brain barrier permeability is an independent predictor of visual outcome in type 2 diabetes, irrespective of the retinal barrier: A longitudinal study.
Abuhaiba SI; Cordeiro M; Amorim A; Cruz Â; Quendera B; Ferreira C; Ribeiro L; Bernardes R; Castelo-Branco M
J Neuroendocrinol; 2018 Jan; 30(1):. PubMed ID: 29247551
[TBL] [Abstract][Full Text] [Related]
59. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
[TBL] [Abstract][Full Text] [Related]
60. Copper transport mediated by nanocarrier systems in a blood-brain barrier in vitro model.
Fehse S; Nowag S; Quadir M; Kim KS; Haag R; Multhaup G
Biomacromolecules; 2014 May; 15(5):1910-9. PubMed ID: 24725062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
